Aging and HIV Infection: A Comparison Between Older HIV-Infected Persons and the General Population

REFERENCES

• Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:863–860.
   Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. HIV/AIDS Sur-veillance Report, 2005. Vol. 17. Rev ed. Atlanta: US Depart-ment of Health and Human Services, CDC; 2007:1–54.
   Google Scholar
• Wohl D, Scherzer R, Heymsfeld S, et al. The associations of regional adipose tissue with lipid and lipoprotein lev-els in HIV-infected men. J Acquir Immune Defic Syndr. 2008;48(1):44–52.
   PubMed Web of Science ®Google Scholar
• Mikhail NE. Lipid abnormalities in patients infected with human immunodeficiency virus. Endocr Pract. 2008;14(4):492–500.
   PubMedGoogle Scholar
• Behrens G, Dejam A, Schmidt H, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS. 1999;13:F63–70.
   PubMed Web of Science ®Google Scholar
• Tebas P, Powderly WG, Claxton S, et al. Accelerated bone mineral loss in HIV-infected patients receiving potent anti-retroviral therapy. AIDS. 2000;14:F63–167.
   PubMed Web of Science ®Google Scholar
• Gallant J, Parish MA, Keruly JC, et al. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis. 2005;40(8):1194–1198.
   PubMed Web of Science ®Google Scholar
• Casau NC. Perspective on HIV infection and aging. Emerging research on the horizon. Clin Infect Dis. 2005;41:855–863.
   PubMed Web of Science ®Google Scholar
• Goulet JL, Fultz SL, Rimland D, et al. Aging and infectious diseases: do patterns of comorbidity vary by HIVstatus, age, and HIV severity? Clin Infect Dis. 2007;45(12):1593–1601.
   PubMed Web of Science ®Google Scholar
• The NHANES 2001–2002 datafiles. Available at: http://www.cdc.gov/nchs/about/major/nhanes/nhanes01-02.htm#Demographics Accessed February 12, 2007.
   Google Scholar
• Wechsler D. Wechsler Adult Intelligence Scale Revised ManuaL San Antonio, DC: Psychological Corporation; 1981.
   Google Scholar
• Anderson KM, Odell PM, Wilson PW, et al. Cardiovascular disease risk profiles. Am Heart J. 1991121: 293–298.
   Google Scholar
• Grading severity of adult and pediatric adverse events. December 2001. Available at: http://rcc.tech-resintl.com/DAIDS%2ORCC%20Forms/TB_ToxicityTables_DAIDS_AE_GradingTable_FinalDec2004.pdf. Accessed October 2008.
   Google Scholar
• Bonora E, Targher G, Alberiche M, et al. Homeostasis model assessment closely mirrors the glucose clamp tech-nique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care. 2000;23:57–63.
   PubMed Web of Science ®Google Scholar
• Merchante N, Macias J, Ramayo E, et al. Insulin resis-tance is not associated with liver fibrosis progression in HIV/Hepatitis C virus-coinfected patients. J Viral HepaL 2006;13(7):449–456.
   PubMed Web of Science ®Google Scholar
• Perazella M, Reilly R. Chronic kidney disease: a new classification and staging system. Hosp Physician. 2003;45:18–22.
   Google Scholar
• Tagle R, Acevedo M, Vidt DG. Microalbuminuria: Is it a valid predictor of cardiovascular risk? Cleveland Clin J Med. 2003;70: 255–261.
   PubMed Web of Science ®Google Scholar
• National Institutes of Health. Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults: the evidence report. Obes Res. 1998;6(2):51S–209S.
   PubMedGoogle Scholar
• Grundy SM, Brewer HB Jr, Cleeman JI, et al; American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to defi-nition. Circulation. 2004;109(3):433–438.
   PubMed Web of Science ®Google Scholar
• Faulkner K. The tale of the T-score: review and perspec-tive. Osteoporos Int. 2005;16:347–352.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteopo-rosis: report of a WHO study group. World Health Organ Tech Rep Ser. 1994;843:1–129.
   PubMed Web of Science ®Google Scholar
• Bosch RJ, Bennett K, Collier AC, et al. Pretreatment factors associated with 3-year (144-week) virologic and immunologic responses to potent antiretroviral therapy. J Acquir Immune Defic Syndr 2007;44(3):268–277.
   PubMed Web of Science ®Google Scholar
• Silverberg MJ, Leyden W, Horberg MA, et al. Older age and the response to and tolerability of antiretroviral ther-apy. Arch Intern Med. 2007;167(7):684–691.
   PubMed Web of Science ®Google Scholar
• Navarro G, Nogueras MM, Segura F, et al. HIV-1 infected patients older than 50 years. PISCIS cohort study. J Infect. 2008;57:64–71.
   PubMed Web of Science ®Google Scholar
• Goodkin K, Shapshak P, Asthana D, et al. Older age and plasma viral load in HIV-1 infection. AIDS. 2004;18(1):S87–98.
   PubMed Web of Science ®Google Scholar
• Hinkin CH, Hardy JH, Mason KI, et al. Medication adherence in HIV-infected adults: effects of patient's age, cognitive status, and substance abuse. AIDS. 2004;18\(suppl 1):S19–25.
   PubMed Web of Science ®Google Scholar
• Chan K, Duque G. Age-related bone loss: old bone, new facts. Gerontology. 2002;48(2):62–71.
   PubMed Web of Science ®Google Scholar
• Boonen S, Singer AJ. Osteoporosis management: impact of fracture type on cost and quality of life in patients at risk for fracture I. Curr Med Res Opin. 2008;24(6): 1781–1788.
   PubMed Web of Science ®Google Scholar
• Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. 903 Study Group. JAMA. 2004;292:191–201.
   PubMed Web of Science ®Google Scholar
• Fausto A, Bongiovanni M, Cicconi P, et al. Potential predic-tive factors of osteoporosis in HIV-positive subjects. Bone. 2006;38:893–897.
   PubMed Web of Science ®Google Scholar
• Tebas P, Powderly WG, Claxton S, et al. Accelerated bone mineral loss in HIV-infected patients receiving potent anti-retroviral therapy. AIDS. 2000;14(4):F63–67.
   PubMed Web of Science ®Google Scholar
• Amorosa V, Tebas P. Bone disease and HIV infection. Clin Infect Dis. 2006;42:108–114.
   PubMed Web of Science ®Google Scholar
• Mondy K, Yarasheski K, Powderly WG, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis. 2003;36:482–490.
   PubMed Web of Science ®Google Scholar
• Dubé MP, Qian D, Edmondson-Melançon H, et al. Pro-spective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy. Clin Infect Dis. 2002;35:475–481.
   PubMed Web of Science ®Google Scholar
• Triant VA, Brown TT, Lee H, et al. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non HIV-infected patients in a large US health-care system. J Clin Endocrinol Metab. 2008;93(9): 3499–3504.
   PubMed Web of Science ®Google Scholar
• National Osteoporosis Foundation. Clinican's guide to pre-vention and treatment of osteoporosis. http://www.natap.org/2008/HIV/NOF_Clinicians_Guide-1.pdf. Accessed September 2009.
   Google Scholar
• Chen D, Misra A, Garg A. Lipodystrophy in human immu-nodeficiency virus-infected patients. J Clin Endocrinol Metab. 2002;87(11):4845–4856
   PubMed Web of Science ®Google Scholar
• Bergersen BM, Sandvik L, Dunlop O, et al. Prevalence of hypertension in HIV-positive patients on highly active retroviral therapy (HAART) compared with HAART-naIve and HIV-negative controls: results from a Norwegian study of 721 patients. Eur J Clin Microbiol Infect Dis. 2003;22(12):731–736.
   PubMed Web of Science ®Google Scholar
• Sattler FR, Qian D, Louie S, et al. Elevated blood pressure in subjects with lipodystrophy. AIDS. 2001;15:2001–2010.
   PubMed Web of Science ®Google Scholar
• Chow DC, Souza SA, Chen R, et al. Elevated blood pres-sure in HIV-infected individuals receiving highly active antiretroviral therapy. HIV Clin Trials. 2003;4(6):411–416.
   PubMed Web of Science ®Google Scholar
• Gazzaruso C, Bruno R, Garzaniti A, et al. Hypertension among HIV patients: prevalence and relationships to insulin resistance to insulin resistance and metabolic syn-drome. J Hypertens. 2003;21:1377–1382.
   PubMed Web of Science ®Google Scholar
• Palacios R, Santos J, Garcia A, et al. Impact of highly active antiretroviral therapy on blood pressure in HIV-infected patients. A prospective study in a cohort of naive patients. HIV Med. 2006;7(1):10–15.
   PubMed Web of Science ®Google Scholar
• Seaberg EC, Munoz A, Lu M, et al. Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS. 2005;19(9):953–960.
   PubMed Web of Science ®Google Scholar
• Thiebaut R, El-Sadr WM, Früs-Moller N, et al. Predictors of hypertension and changes of blood pressure in HIV-infected patients. Antivir Ther 2005;10(7):811–823.
   PubMed Web of Science ®Google Scholar
• Jerico C, Knobel H, Montero M, et al. Hypertension in HIV-infected patients: prevalence and related factors. Am J Hypertens. 2005;18:1396–1401.
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services, Centers for Disease Control and Prevention. Preventing Heart Dis-ease and Stroke: Addressing the Nation's Leading Killers 2005. Atlanta: Centers for Disease Control and Prevention; 2005.
   Google Scholar
• Hurley L, Leyden W, Xu L, et al. Updated surveillance of cardiovascular event rates among HIV-infected and HIV-uninfected Californians, 1996 to 2008. In: Program and abstracts of the 16th CR01; 2009; Montreal, Canada. Abstract 710.
   Google Scholar
• Lichtenstein K, Armon C, Buchacz K, et al. Analysis of cardiovascular risk factors in the HIV outpatient study. In: Program and abstracts of the 13th CR01; 2006; Denver, Colorado. Abstract 735.
   Google Scholar
• Danziger J. Importance of low-grade albuminuria. Mayo Clin Proc. 2008;83(7):806–812.
   PubMed Web of Science ®Google Scholar
• Dube MP, Stein JH, Aberg JA, et al. Guidelines for the eval-uation and management of dyslipidemia in HIV-infected adults receiving antiretroviral therapy: recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003;37:613–627.
   PubMed Web of Science ®Google Scholar
• Hurlimann D, Chenevard R, Ruschitzka F, et al. Effects of statins on endothelial function and lipid profile in HIV infected persons receiving protease inhibitor-containing antiretroviral therapy: a randomized double blind cross-over trial. Heart. 2006;92:110–112.
   PubMed Web of Science ®Google Scholar
• Grunfeld C, Delaney J, Wanke C, et al. HIV Infection is an independent risk factor for atherosclerosis similar in mag-nitude to traditional cardiovascular disease risk factors. In: Program and abstracts of the 16th CR01; 2009; Montreal, Canada. Abstract 146.
   Google Scholar
• Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Lundgren JD, Babiker A, El-Sadr W, et al. Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ cell counts and HIV RNA lev-els during follow-up. J Infect Dis. 2008;197(8):1145–1155.
   PubMed Web of Science ®Google Scholar
• Tebas P, Henry WK, Matining R, et al. Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular risk. PLoS ONE. 2008;3(4):e2021.
   PubMed Web of Science ®Google Scholar
• Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in can-cer risk among people with AIDS in the United States 1980-2002. AIDS. 2006;20:1645–1654.
   PubMed Web of Science ®Google Scholar
• Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV cohort study: associations with immunode-ficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst. 2005;97(6):425–432.
   PubMed Web of Science ®Google Scholar
• Silverberg MJ, Neuhaus J, Bower M, et al. Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS. 2007;21:1957–1963.
   PubMed Web of Science ®Google Scholar
• Spano JP, Costagliola D, Katlama C, et al. AIDS-related malignancies: state of the art and therapeutic challenges. J Clin OncoL 2008;26(29):4834–4842.
   PubMed Web of Science ®Google Scholar
• Silverberg MJ, Abrams DI. AIDS-defining and non AIDS-defining malignancies: cancer occurrence in the antiretroviral therapy era. Curr Opin Oncol. 2007;19: 446–451.
   PubMed Web of Science ®Google Scholar
• Cadranel J, Garfield D, Lavoie A, et al. Lung cancer in HIV patients: facts, questions and challenges. Thorax. 2006;61:1000–1008.
   PubMed Web of Science ®Google Scholar
• Daling JR, Weiss NS, Hislop TG, et al. Sexual practices, sexually transmitted diseases, and the incidence of anal cancer. N Engl J Med. 1987;317:973–977.
   PubMed Web of Science ®Google Scholar
• Ruiz P, Fernandez F. HIV/AIDS among older adults. In: Fernandez F, Ruiz P, eds. Psychiatric Aspect of HIV/AIDS. Baltimore: Lippincott Williams & Wilkins; 2006: 267–276.
   Google Scholar
• Valcour V, Paul R. HIV infection and dementia in older adults. Clin Infect Dis. 2006;42:1449–1454.
   PubMed Web of Science ®Google Scholar
• Clifford DB. HIV-associated neurocognitive disease con-tinues in the antiretroviral era. Top HIV Med. 2008;16(2): 94–98.
   PubMedGoogle Scholar
• Kirk JB, Goetz MB. Human immunodeficiency virus in an aging population, a complication of success. J Am Geriatr Soc. September 28,2009. [Epub ahead of print]
   Google Scholar
• Effros RB, Fletcher CV, Gebo K, et al. Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions. Clin Infect Dis. 2008;47(4):542–553.
   PubMed Web of Science ®Google Scholar